Sanofi and Regeneron Report Phase 3 PART A Results for Dupixent in Alopecia Areata

Sanofi and Regeneron today announced results from the Phase 3 PART A trial evaluating Dupixent (dupilumab) in adults with severe alopecia areata. The trial met its primary endpoint, demonstrating a significantly higher proportion of patients achieving at least 80% scalp hair coverage compared to placebo at week 36. These results support the potential of Dupixent in alopecia areata.